| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Decoding liver injury in cystic fibrosis: How to tell drug-induced liver injury from cystic fibrosis liver disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Junseo Lee, Anuroop Yekula, Ava Wexler, William Zhuang, Ashwath Elangovan, Joshua Rosario, Philomena Burger, Gopal Ramaraju, Benyam Addissie, Nicholas Lim, Michael R Narkewicz and Patrick Twohig |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Patrick Twohig, Assistant Professor, FRCPC, MD, Department of Gastroenterology and Hepatology, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14682, United States. patrick_twohig@urmc.rochester.edu |
| Key Words |
Cystic fibrosis; Liver diseases; Cystic fibrosis transmembrane conductance regulator; Drug-induced liver injury; Cholestasis |
| Core Tip |
Cystic fibrosis (CF) liver disease is a major comorbidity in CF, complicated by progressive cholestasis and overlapping risk of drug-induced liver injury, including from CF transmembrane conductance regulator modulators. This study synthesizes literature on pathogenesis, clinical features, diagnostics, and management to aid in distinguishing advanced CF liver disease progression from drug induced liver injury. Key differentiators include biochemical profiles, imaging, treatment response, and histology. Early recognition and a multidisciplinary approach are essential to optimize therapy, preserve liver function, and balance the benefits and risks of CF transmembrane conductance regulator modulators. |
| Publish Date |
2026-03-02 08:37 |
| Citation |
Lee J, Yekula A, Wexler A, Zhuang W, Elangovan A, Rosario J, Burger P, Ramaraju G, Addissie B, Lim N, Narkewicz MR, Twohig P. Decoding liver injury in cystic fibrosis: How to tell drug-induced liver injury from cystic fibrosis liver disease. World J Gastroenterol 2026; 32(10): 114946 |
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i10/114946.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v32.i10.114946 |
